

PG3602USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Campbell et al.

Serial No.: 09/830,836

Group Art Unit: 1625

File Date: May 1, 2001

Examiner: S.E. Perlinger

For: Pyrazolopyridine Derivatives as Selective COX-2 Inhibitors

Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants respectfully request the Examiner take notice of the following copending patent applications. The U.S. serial numbers correspond to the WIPO publications as indicated in the chart below. The WIPO publications are also submitted on form 1449 attached to this Information Disclosure Statement.

Pub No.	USN
WO99/12930	10/974893
WO03/077920	10/506,934
WO00/26216	09/830,836
WO02/18374	10/362745
" "	11/165073
WO02/096886	10/477546
WO02/096427	10/477819
" "	11/119653
WO03/14091	10/486,001
WO04/018452	10/524462
WO02/096885	10/477547
" "	11/110118
WO04/048344	10/535806
WO04/024691	10/527799
WO01/56573	10/786423

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: Ref. 27-87
☐ Copies of the references were submitted in parent application _____ (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.


- A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. ☒ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311, whichever occurs first.
- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☒ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,


J. Scott Young
Registration No. 45,582

Date: August 17, 2006
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8160
Facsimile: (919) 483-7988

**FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT****ATTORNEY DOCKET NO.**
PG3602USW**SERIAL NO.**
09/830,836**APPLICANT:** Cambell et al.**FILING DATE:**
May 1, 2001**GROUP**
1625**U.S. PATENT DOCUMENTS**

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date (If Appropriate)
	1	2003/0018023	Jan. 23, 2003	Pinto et al.			
	2	2003/0013717	Jan. 16, 2003	Mangel et al.			
	3	3,149,109	Sept. 15, 1964	Neustaedter et al.			
	4	3,592,895	July 13, 1971	Hepworth et al.			
	5	5,474,995	Dec. 12, 1995	Ducharme et al.			
	6	5,760,068	June 2, 1998	Talley et al.			
	7	5,849,753	Dec. 15, 1998	Kleemann et al.			
	8	5,972,842	Oct. 26, 1999	Maier et al.			
	9	5,972,986	Oct. 26, 1999	Seibert et al.			
	10	5,985,886	Nov. 16, 1999	Elliott et al.			
	11	6,020,343	Feb. 1, 2000	Belley et al.			
	12	6,121,202	Sept. 19, 2000	Karp et al.			
	13	6,153,619	Nov. 28, 2000	Wood et al.			
	14	6,248,892	June 19, 2001	Noerenberg et al.			
	15	6,306,866	Oct. 23, 2001	Wood et al.			
	16	6,313,072	Nov. 6, 2001	Scheiblich et al.			
	17	6,355,799	Mar. 12, 2002	Gupta et al.			
	18	6,451,794	Sept. 17, 2002	Beswick et al.			
	19	6,498,166	Dec. 24, 2002	Campbell et al.			
	20	6,756,498	June 29, 2004	Fitzgerald et al.			
	21	6,759,413	July 6, 2004	Mangel et al.			
	22	6,780,869	Aug. 24, 2004	Groen et al.			
	23	6,780,870 B2	Aug. 24, 2004	Carter et al.			
	24	6,803,463	Oct. 12, 2004	Mathews et al.			
	25	6,831,097	Dec. 14, 2004	Beswick et al.			
	26	6,861,249	Mar. 1, 2005	Kent			

Continue on page

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	27	DE 19909541	Mar. 4, 1999	GERMANY		Abstract only
	28	DE 19651099	June 10, 1998	GERMANY		
	29	DE 19708928	Sept. 10, 1998	GERMANY		
	30	DE 19831246	Jan. 1, 2000	GERMANY		
	31	EP 0723960	July 31, 1996	EUROPE		
	32	EP 0820996	Jan. 28, 1998	EUROPE		
	33	JP 09241161	Sept. 16, 1997	JAPAN		
	34	JP 2000026421	Jan. 25, 2000	JAPAN		
	35	JP 2001081074	Mar. 27, 2001	JAPAN		
	36	JP 2001252044	Nov. 22, 1999	JAPAN		
	37	JP 9241161	Sept. 16, 1997	JAPAN		Abstract only
	38	WO 96/07641	Mar. 14, 1996	WIPO		Abstract only
	39	WO 96/24585	Aug. 15, 1996	WIPO		

Continue on page 2

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

Continue on page

EXAMINER**DATE CONSIDERED**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PG3602USW		SERIAL NO. 09/830,836	
				APPLICANT: Campbell et al.			
				FILING DATE: May 1, 2001		GROUP 1625	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	40	WO 96/41625	Dec. 27, 1996	WIPO			
	41	WO 96/41645	Dec. 27, 1996	WIPO			
	42	WO 97/38996	Oct. 23, 1997	WIPO			
	43	WO 98/03484	Jan. 29, 1998	WIPO			
	44	WO 98/16227	Apr. 23, 1998	WIPO			
	45	WO 98/24782	June 11, 1998	WIPO			
	46	WO 99/01439	Jan. 14, 1999	WIPO			
	47	WO 99/12930	Mar. 18, 1999	WIPO			
	48	WO 99/21837	May 6, 1999	WIPO			
	49	WO 99/55668	April 11, 1999	WIPO			X Abstract
	50	WO 00/26216	May 11, 2000	WIPO			
	51	WO 00/47553	Aug. 17, 2000	WIPO			
	52	WO 00/52008	Sept. 8, 2000	WIPO			
	53	WO 01/38311	May 31, 2001	WIPO			
	54	WO 01/45703	June 28, 2001	WIPO			
	55	WO 01/46194	June 28, 2001	WIPO			
	56	WO 01/41760	June 14, 2001	WIPO			
	57	WO 01/56573	Aug. 9, 2001	WIPO			
	58	WO 01/58881	Aug. 16, 2001	WIPO			
	59	WO 01/62233	Aug. 30, 2001	WIPO			
	60	WO 01/83479	Nov. 8, 2001	WIPO			
	61	WO 02/00647	Jan. 3, 2002	WIPO			
	62	WO 02/00655	Jan. 3, 2002	WIPO			
	63	WO 02/18374	Mar. 7, 2002	WIPO			
	64	WO 02/44137	June 6, 2002	WIPO			X Abstract
	65	WO 02/55484	July 18, 2002	WIPO			X Abstract
	66	WO 02/59122	Aug. 1, 2002	WIPO			
	67	WO 02/96427	Dec. 5, 2002	WIPO			
	68	WO 02/96885	Dec. 5, 2002	WIPO			
	69	WO 02/96886	Dec. 5, 2002	WIPO			
	70	WO 02/100838	Dec. 19, 2002	WIPO			
	71	WO 03/04472	Jan. 16, 2003	WIPO			
	72	WO 03/14091	Feb. 20, 2003	WIPO			
	73	WO 03/14092	Feb. 20, 2003	WIPO			
	74	WO 03/22219	Mar. 20, 2003	WIPO			
	75	WO 03/77920	Sept. 25, 2003	WIPO			
Continue on page <u>3</u>							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PG3602USW		SERIAL NO. 09/830,836	
				APPLICANT: Campbell et al.			
				FILING DATE: May 1, 2001		GROUP 1625	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	76	WO 04/18452	Mar. 4, 2003	WIPO			
	77	WO 04/24691	Mar. 25, 2004	WIPO			
	78	WO 04/48344	June 10, 2004	WIPO			
	79	WO 05/16924	Feb. 24, 2005	WIPO			
Continue on page							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	80	Casanova, B., et al. "A Critical Review of the current Pathogenesis of Multiple Sclerosis and Possible Future Trends." Pub Med Abstract 9Rev. Neurol. 28(9), May 1999, pgs. 909-915.					
	81	Damasio, A.R., et al. Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, Vol. 2, pp. 1992-1996, 1996.					
	82	Douglas, R.G., Jr. "Introduction to Viral Diseases: Cecil Textbook of Medicine, 20 th Edition, Vol. 2, pp. 1739-1747, 1996.					
	83	Preston, J.W., et al. Rationalizing Cyclooxygenase (COX) Inhibition for Maximal Efficacy and Minimal Adverse Events + Abstract, Am. J. Med. 107(6A):78S-88S; Discussion 89S), December 1999.					
	84	Layzer, R.B., et al. Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20 th Edition, Vol. 2, pp. 2050-2057, 1996.					
	85	Naesdal, J. et al. "Gastro-Duodenal Protection in an Era of Cyclo-Oxygenase-2-Selective Nonsteroidal Anti-inflammatory Drugs." PubMed Abstract, Eur J Gastroenterol Hepatol, 13(12):1401-1406, December 2001.					
	86	Simone, J.V., et al. "Oncology: Introduction, Cecil Textbook of Medicine, 20 th Edition, Vol. 1, pp. 1004-10, 1996.					
	87	Stanghellini, V., et al. "Risk Indicators of Delayed Gastric Emptying of Solids in Patients With Functional Dyspepsia." Gastroenterology, 110(4), 1996, pgs 1036-1042.					
Continue on page							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							